These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 21470623

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
    Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
    Chen T, Hou SX, Sun YY, Zheng Y.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov; 37(6):934-7. PubMed ID: 17236598
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles.
    Ma HL, Qi XR, Ding WX, Maitani Y, Nagai T.
    J Biomed Mater Res A; 2008 Mar 01; 84(3):598-606. PubMed ID: 17618488
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids.
    Hornung A, Poettler M, Friedrich RP, Zaloga J, Unterweger H, Lyer S, Nowak J, Odenbach S, Alexiou C, Janko C.
    Molecules; 2015 Sep 30; 20(10):18016-30. PubMed ID: 26437393
    [Abstract] [Full Text] [Related]

  • 40. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles.
    Cole AJ, David AE, Wang J, Galbán CJ, Yang VC.
    Biomaterials; 2011 Sep 30; 32(26):6291-301. PubMed ID: 21684593
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.